



Transparency notification

Brussels (Belgium), 12 January 2017 – 20:00 (CET) – regulated information

1. Summary of the notification:

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification with the FSMA.

The transparency notification dated 12 January 2017 has been submitted in accordance with article 18 *juncto* article 6 of the royal decree of 14 November 2008 on the disclosure of large shareholdings, due to voting rights relating to voting securities of UCB SA dropping below the 3% minimum threshold (on a consolidated basis) on 6 January 2017. The variation is due to delivery of shares to employees in the framework of Long Term Incentive programs of the UCB group.

During 2016, there was no change with regard to the assimilated financial instruments included in the previous transparency notification of 8 January 2016.

On 6 January 2017, UCB SA/NV (taking into account the holding of its affiliates) owned 5 825 262 UCB shares with voting rights (versus 6 250 222 UCB shares in its previous notification dated 8 January 2016), representing 2.99% of the total number of shares issued by the company (194 505 658) (versus 3.21% in the notification dated 8 January 2016).

2. Content of the notification:

The transparency notification dated 12 January 2017 includes the following information:

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Person subject to the notification requirement:** UCB SA/NV, Allée de la recherche 60, 1070 Brussels (Anderlecht).
- **Date on which the threshold is crossed :** 6 January 2017.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194 505 658.

- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
	Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
UCB SA/NV	4.008.213	3.076.436		1,58%	
UCB Fipar SA	2.242.009	2.748.826		1,41%	
Subtotal	6.250.222	5.825.262		2,99%	
TOTAL		5.825.262	0	2,99%	0,00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
UCB SA/NV	options	25/09/2017	Every day until expira	166.665	0,09%	physical
UCB SA/NV	options	26/03/2018	(idem)	166.667	0,09%	physical
UCB SA/NV	options	25/06/2018	(idem)	166.668	0,09%	physical
UCB SA/NV	options	25/09/2017	(idem)	166.666	0,09%	physical
UCB SA/NV	options	26/03/2018	(idem)	166.668	0,09%	physical
UCB SA/NV	options	25/06/2018	(idem)	166.666	0,09%	physical
UCB Fipar SA	options	31/03/2020	(idem)	170.840	0,09%	physical
UCB Fipar SA	options	31/03/2020	(idem)	264.160	0,14%	physical
TOTAL				1.435.000	0,74%	

TOTAL (A & B)	de droits de vote	% de droits de vote
CALCULER	7.263.362	3,73%

- **Chain of controlled undertakings through which the holding is effectively held:** UCB SA/NV indirectly controls UCB Fipar SA.
- **Additional information:**

The disclosure obligation arose due to voting rights relating to voting securities of UCB SA dropping below the 3% minimum threshold (on a consolidated basis). The variation is due to delivery of shares to employees in the framework of Long Term Incentive programs of the UCB group.

During 2016, there was no change with regard to the assimilated financial instruments included in the previous transparency notification of 8 January 2016.

3. Further information:

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of €3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news